BLADDER CANCER: METABOLISM OF CARCINOGENS & PREVENTION
BLADDER CANCER: METABOLISM OF CARCINOGENS & PREVENTION
批准号:
3167928
负责人:
TERRY V ZENSER
金额:
$13.11万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1980
资助国家:
美国
项目状态:
已结题
起止时间:
1980-09-01 至 1989-06-30
关键词:
DNA aspirin autoradiography bladder neoplasm cancer prevention carcinogenesis inhibitor carcinoma chemical addition chemical carcinogen covalent bond cyclic amine diet eicosanoid metabolism enzyme substrate glutathione high performance liquid chromatography human tissue kidney metabolism mass spectrometry nuclear magnetic resonance spectroscopy nutrition related tag oxidation peroxidases prostaglandin endoperoxide synthase radioimmunoassay radiopharmacology radiotracer renal medulla reversed phase chromatography tissue /cell culture toxicant screening toxin metabolism urinalysis
中文摘要
我们建议继续界定启动的具体机制
化学诱发的膀胱癌 的
选择N-[4-(5-硝基-2-呋喃基)-2-噻唑基]甲酰胺(FANFT)模型
由于高发病率允许实验设计的灵活性,
所需病变的位置。 构成我们建议基础的假设是:
1)某些特定的生理和代谢功能负责
递送高浓度的更接近脱甲酰化的
致癌物质ANFT对尿路上皮的影响。 2)代谢活化发生在
前列腺素H合酶(PHS)氧化ANFT的尿路上皮细胞a
可能的激活机制。 也可能涉及其他途径。 第三章
降低膀胱上皮可接近的ANFT量的药剂,
防止膀胱中的活化和/或防止活化的中间体
结合DNA将降低FANFT诱导的膀胱癌的发生率。
FANFT-ANFT代谢和处置将通过完整大鼠和动物模型进行评估。
豚鼠,分别对以下物质敏感和耐药的种属
FANFT诱发的膀胱癌。 将评估靶组织代谢
用来自大鼠、人和豚鼠的尿路上皮细胞。 组织分布,
共价结合和色谱分离代谢物
使用14 C-和35 S-标记的
FANFT-ANFT。 将从大鼠中纯化的肾FANFT脱甲酰基酶进行纯化。
表征了 PHS的尿路上皮细胞合成类花生酸底物
也将被评估。 生物学评估将包括细胞
ANFT及其对尿路上皮细胞的毒性评价
代谢物。 体内方法将使用两阶段FANFT模型,
评价饮食因素对生理(尿液pH值)和代谢的影响
FANFT启动的(激活)参数。 每一组实验将
不断测试我们的假设,通过选择代理人,
代谢和处置和改善致病过程。 数据
从这次更新中获得的将对理论和
膀胱癌的治疗方法 理论意义涉及到
确定涉及引发的途径,
重要性涉及预防治疗策略的发展。
英文摘要
We propose to continue defining specific mechanisms involved in initiation
of chemically-induced bladder cancer. The
N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) model was chosen
because of flexibility in experimental design permitted by a high incidence
of the desired lesion. Hypotheses forming the basis of our proposal are:
1) Certain specific physiologic and metabolic functions are responsible for
the delivery of high concentrations of the more proximate deformylated
carcinogen, ANFT, to urothelium. 2) Metabolic activation occurs in
urothelial cells with oxidation of ANFT by prostaglandin H synthase (PHS) a
likely mechanism of activation. Other pathways may also be involved. 3)
Agents which decrease the amount of ANFT accessible to bladder epithelium,
prevent activation in bladder and/or prevent activated intermediates from
binding DNA will reduce the incidence of FANFT-induced bladder cancer.
FANFT-ANFT metabolism and disposition will be assessed by intact rat and
guinea pig, species susceptible and resistant, respectively, to
FANFT-induced bladder cancer. Target tissue metabolism will be assessed
with urothelial cells from rat, human and guinea pig. Tissue distribution,
covalent binding and chromatographically separable metabolite
determiantions will be facilitated by the use of 14C- and 35S-labeled
FANFT-ANFT. Renal FANFT deformylase purified from rat will be
characterized. Urothelial cell synthesis of eicosanoid substrates of PHS
will also be assessed. Biologic assessment will include cell
transformation and urothelial cell toxicity evaluation of ANFT and its
metabolites. The in vivo method will use the two-stage FANFT model to
evaluate effects of dietary factors on physiologic (urine pH) and metabolic
(activation) parameters of FANFT initiation. Each set of experiments will
continuously test our hypotheses by the selection of agents which alter
metabolism and disposition and ameliorate pathogenic processes. Data
obtained from this renewal will have a profound impact on theoretical and
practical aspects of bladder cancer. Theoretic signfiicance relates to
determiation of pathways involved in initiation while practical
significance relates to development of therapeutic strategies of prevention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
METABOLISM OF N ACETYLBENZIDINE & INITIATION OF BLADDER CANCER
-
批准号:7180145
-
项目类别:
-
资助金额:$0.65万
-
财政年份:2005
-
负责人:TERRY V ZENSER
-
依托单位:
N-ACETYLBENZIDINE DNA ADDUCT FORMATION BY BLADDER CELLS
-
批准号:6173107
-
项目类别:
-
资助金额:$21.16万
-
财政年份:1998
-
负责人:TERRY V ZENSER
-
依托单位:
N-ACETYLBENZIDINE DNA ADDUCT FORMATION BY BLADDER CELLS
-
批准号:2696342
-
项目类别:
-
资助金额:$21.19万
-
财政年份:1998
-
负责人:TERRY V ZENSER
-
依托单位:
N-ACETYLBENZIDINE DNA ADDUCT FORMATION BY BLADDER CELLS
-
批准号:2895754
-
项目类别:
-
资助金额:$22.54万
-
财政年份:1998
-
负责人:TERRY V ZENSER
-
依托单位:
Metabolism and Carcinogenicity of Heterocyclic Amines
-
批准号:6943094
-
项目类别:
-
资助金额:$25.55万
-
财政年份:1998
-
负责人:TERRY V ZENSER
-
依托单位:
Metabolism and Carcinogenicity of Heterocyclic Amines
-
批准号:7115019
-
项目类别:
-
资助金额:$24.95万
-
财政年份:1998
-
负责人:TERRY V ZENSER
-
依托单位:
Metabolism and Carcinogenicity of Heterocyclic Amines
-
批准号:7251458
-
项目类别:
-
资助金额:$24.23万
-
财政年份:1998
-
负责人:TERRY V ZENSER
-
依托单位:
Metabolism and Carcinogenicity of Heterocyclic Amines
-
批准号:6731779
-
项目类别:
-
资助金额:$25.55万
-
财政年份:1998
-
负责人:TERRY V ZENSER
-
依托单位:
Metabolism and Carcinogenicity of Heterocyclic Amines
-
批准号:6804122
-
项目类别:
-
资助金额:$25.55万
-
财政年份:1998
-
负责人:TERRY V ZENSER
-
依托单位:
BLADDER CANCER: METABOLISM OF CARCINOGENS & PREVENTION
-
批准号:3167935
-
项目类别:
-
资助金额:$12.69万
-
财政年份:1980
-
负责人:TERRY V ZENSER
-
依托单位:
BLADDER CANCER: METABOLISM OF CARCINOGENS & PREVENTION
-
批准号:3167934
-
项目类别:
-
资助金额:$12.74万
-
财政年份:1980
-
负责人:TERRY V ZENSER
-
依托单位:
BLADDER CANCER: CARCINOGENS AND PREVENTION
-
批准号:3167933
-
项目类别:
-
资助金额:$12.87万
-
财政年份:1980
-
负责人:TERRY V ZENSER
-
依托单位:
AROMATIC AND HETEROCYCLIC AMINE INDUCED BLADDER CANCER
-
批准号:3889504
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:TERRY V ZENSER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Aspirin调控AKT/Foxo3a/BIM通路延缓吡咯替尼耐药作用机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:田武国
-
依托单位:
Aspirin与自噬通路及核转录因子FoxG1在听觉系统退行性变中的协同调控机制研究
-
批准号:81800915
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:贺祖宏
-
依托单位:
Aspirin联合牙周膜干细胞再生全脱位牙牙周组织机制研究
-
批准号:81760190
-
项目类别:地区科学基金项目
-
资助金额:32.0万元
-
批准年份:2017
-
负责人:王璇
-
依托单位:
可注射温敏型水凝胶缓释Aspirin碳点和EPO促牙周组织再生的研究
-
批准号:81600879
-
项目类别:青年科学基金项目
-
资助金额:17.0万元
-
批准年份:2016
-
负责人:徐晓薇
-
依托单位:
Aspirin协同IFN-α抑制肝癌转移复发的作用及机制研究
-
批准号:30972889
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2009
-
负责人:智绪亭
-
依托单位:
胃癌microRNA特异表达与靶基因调控及Aspirin的作用
-
批准号:30873099
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2008
-
负责人:王雪融
-
依托单位: